Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $13.00 → $9.00 | Outperform | Raymond James |
| 11/15/2021 | $20.00 | Outperform | Evercore ISI Group |
| 10/27/2021 | $12.00 | Buy | BTIG Research |
| 10/25/2021 | $13.00 | Outperform | Raymond James |
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi
6-K - LumiraDx Ltd (0001685428) (Filer)
6-K - LumiraDx Ltd (0001685428) (Filer)
6-K - LumiraDx Ltd (0001685428) (Filer)
Gainers Syra Health (NASDAQ:SYRA) shares rose 21.2% to $1.5 during Monday's after-market session. The market value of their outstanding shares is at $9.6 million. Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 13.15% to $2.58. The market value of their outstanding shares is at $9.3 million. MaxCyte (NASDAQ:MXCT) shares rose 10.23% to $5.06. The company's market cap stands at $524.0 million. Elevation Oncology (NASDAQ:ELEV) shares rose 7.73% to $1.95. The market value of their outstanding shares is at $82.7 million. MSP Recovery (NASDAQ:LIFW) stock increased by 5.82% to $2.0. The market value of their outstanding shares is at $28.8 million. BrainsWay (NASDAQ:BWAY) stock mo
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The S&P 500 also rose, gaining, 1.11% to 4,749.41. Check This Out: Don't Miss These 3 Consumer Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts Leading and Lagging Sectors Information technology shares jumped by 2.1% on Monday. In trading on Monday, energy shares fell by 2.1%. Top Headline Commercial Metals Company (NYSE:CMC) posted upbeat earnings for its first quarter on Monday. Commercial Metals posted adjusted earnings of $1.63 per share, beatin
Shares of RxSight, Inc. (NASDAQ:RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41. RxSight shares jumped 20% to $44.31 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Harpoon Therapeutics, Inc. (NASDAQ:HARP) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash. Ambrx Biopharma Inc. (NASDAQ:AMAM) jumped 98.1% to $27.00 after Johnson & Johnson announced it will acquire the company in an all-cash merger for a total equity value
SC 13G/A - LumiraDx Ltd (0001685428) (Subject)
SC 13G/A - LumiraDx Ltd (0001685428) (Subject)
SC 13D/A - LumiraDx Ltd (0001685428) (Subject)
Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously
Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00
BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi
LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights. LumiraDx Second Quarter 2023 Financial Results Conference Call Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time Live Call/Webcast: Register to join by phone here. View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar A replay of the webcast will be available on the Inv
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c